SCHEMBL4161565

SCHEMBL4161565

CC1(C)CN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CCN1CC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 3/20 0.61
GPX4 P36969 4/20 0.48
CACNA2D1 P54289 5/20 0.46
CACNB1 Q02641 5/20 0.46
CACNA1B Q00975 4/20 0.46
CACNA1C Q13936 4/20 0.46
CACNA1G O43497 1/20 0.46
CACNA1A O00555 1/20 0.45
SLC6A2 P23975 3/20 0.45
SLC6A4 P31645 3/20 0.45
DRD3 P35462 3/20 0.45
SLC6A3 Q01959 3/20 0.45
KCNH2 Q12809 3/20 0.45
CHRM2 P08172 2/20 0.45
HTR1A P08908 2/20 0.45
ADRA2A P08913 2/20 0.45
CHRM1 P11229 2/20 0.45
DRD1 P21728 2/20 0.45
TBXA2R P21731 2/20 0.45
ADRA1A P35348 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4149476 0.99 SLC6A9 (0.60) SLC6A9GPX4CACNA2D1CACNB1CACNA1B
SCHEMBL4139616 0.76 SLC6A9 (1.00) SLC6A9GPX4CACNA2D1CACNB1CACNA1B
SCHEMBL4556324 0.76 OPRD1 (0.42) SLC6A9CHRM1OPRM1
Hydrochloric Acid SCHEMBL4150496 0.75 SLC6A9 (0.97) SLC6A9GPX4CACNA2D1CACNB1CACNA1B
SCHEMBL28935916 0.73 SLC6A9 (0.91) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4136017 0.73 SLC6A9 (0.91) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
SCHEMBL4145296 0.73 SLC6A9 (1.00) SLC6A9GPX4CACNA2D1CACNB1CACNA1B
SCHEMBL4145289 0.73 SLC6A9 (1.00) SLC6A9GPX4CACNA2D1CACNB1CACNA1B
Hydrochloric Acid SCHEMBL4140455 0.72 SLC6A9 (0.89) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C
Hydrochloric Acid SCHEMBL4149241 0.72 SLC6A9 (0.97) SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 US claimed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 EP claimed
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2012-08-02 US claimed
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS HITCHCOCK STEPHEN 2009-09-10 US claimed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 US claimed
EP-2041088-A1 GLYCINE TRANSPORTER-1 INHIBITORS Amgen Inc. (US) 2009-04-01 EP claimed
WO-2008002583-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2008-01-03 WO claimed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 US claimed
US-9663476-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
EP-2947067-A1 Glycine transporter-1 inhibitors Amgen, Inc (US) 2015-11-25 EP disclosed
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2015-10-29 US disclosed
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 US disclosed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 EP disclosed
EP-2565183-A1 Glycine transporter-1 inhibitors Amgen Inc. (US) 2013-03-06 EP disclosed
US-8183244-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2012-05-22 US disclosed
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS HITCHCOCK STEPHEN 2009-09-10 US disclosed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 US disclosed
EP-2041088-A1 GLYCINE TRANSPORTER-1 INHIBITORS Amgen Inc. (US) 2009-04-01 EP disclosed
WO-2008002583-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2008-01-03 WO disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227595-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885GPX4 2136/4885CACNA2D1 3216/4885
US-20120195985-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC6A5, SLC1A2 SLC6A9 6/4885GPX4 2459/4885CACNA2D1 3030/4885
US-20080004289-A1 Glycine transporter-1 inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885GPX4 2136/4885CACNA2D1 3216/4885
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885GPX4 2136/4885CACNA2D1 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.